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Abstract
Accurate conversion of magnetic resonance spectra to quantitative units of concentration generally requires compensation
for differences in coil loading conditions, the gains of the various receiver amplifiers, and rescaling that occurs during post-
processing manipulations. This can be efficiently achieved by injecting a precalibrated, artificial reference signal, or pseudo-
signal into the data. We have previously demonstrated, using in vitro measurements, that robust pseudo-signal injection
can be accomplished using a second coil, called the injector coil, properly designed and oriented so that it couples
inductively with the receive coil used to acquire the data. In this work, we acquired nonlocalized phosphorous magnetic
resonance spectroscopy measurements from resting human tibialis anterior muscles and used pseudo-signal injection to
calculate the Pi, PCr, and ATP concentrations. We compared these results to parallel estimates of concentrations obtained
using the more established phantom replacement method. Our results demonstrate that pseudo-signal injection using
inductive coupling provides a robust calibration factor that is immune to coil loading conditions and suitable for use in
human measurements. Having benefits in terms of ease of use and quantitative accuracy, this method is feasible for clinical
use. The protocol we describe could be readily translated for use in patients with mitochondrial disease, where sensitive
assessment of metabolite content could improve diagnosis and treatment.
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Introduction
One of the most enticing features of magnetic resonance
spectroscopy (MRS) is its feasibility for use as a noninvasive
biochemical assay. This potential arises from the fact that the
amplitudes of the peaks in the processed spectra are directly
proportional to the number of excited nuclei within the measure-
ment volume. Unfortunately, the proportionality is also affected by
a variety of other parameters such as pulse sequence timing
parameters and their interaction with relevant relaxation times, B1
field homogeneity and its effects on signal excitation and reception
sensitivity, etc. The level of diligence required to measure and/or
compensate for all of these parameters is technically challenging
for research sites [1,2] and beyond the capabilities of most clinical
sites so nearly all MRS measurements are reported as relative
changes or in terms of ratios, which can be difficult to interpret.
When making the conversion to units of concentration, one of
the most cumbersome parameters to address is RF coil loading,
which determines the amplitude of the current generated in the
coil used to receive the MR signal (and therefore the subsequent
amplitude of the peak in the spectrum) per unit of excited nuclei in
the sample volume. Coil loading is dependent on the electrical
properties of the coil, the geometry of the magnetic flux lines the
coil produces, and the concentration and distribution of
electrolytes in the sample. It is difficult to measure accurately
and can vary substantially between subjects or even for the same
subject depending on the relative position of the coil.
In 1997, Barantin, et al [3] demonstrated how an artificially
injected reference signal can be used to compensate for coil
loading conditions. The method they developed, Electronic
REference To access In vivo Concentrations (ERETIC), uses
either a broad band antenna [3,4] or the second coil in a high
resolution probe [5–7] to broadcast an amplitude modulated
signal that replicates a free induction decay (FID). Radiation
coupling between the antenna and the RF coil creates an artificial
peak, or pseudo-peak, in the processed spectrum. The amplitude
of the pseudo-peak is first calibrated using a phantom with a
known concentration of an MR-visible molecule. Transmission of
the same pseudo-signal during subsequent measurements creates a
scale factor that is used to convert peak amplitudes to units of
concentration. This method can be applied to any MR-visible
nucleus. The user sets the amplitude, frequency, phase, and line-
width of the pseudo-peak as desired. The frequency is then set to a
convenient location, within the acquisition bandwidth, but not
overlapping real peaks. The electronically injected reference signal
is readily available and eliminates the need to maintain stable
biochemical samples for use as external references.
Implementation of the ERETIC method in humans is hindered
by the use of radiation coupling to inject the artificial signal. A
broadcasted signal can reflect off, or be absorbed by, objects in the
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including the sample itself, could alter the coupling between the
transmitter and the receive coil and change the factor of
proportionality established during the calibration session. This
places constraints on implementation that are impractical for
clinical sites so, while the original ERETIC measurements were
reported in humans [3] nearly all subsequent implementations
were in vitro [4–25] or in small animals [26], where the sample
size was small and consistent. The recent work of Heinzer-
Schweizer, et al. [27] is a notable exception to this pattern.
We have developed a method that provides the same
advantages as the ERETIC method but creates a more stable
reference signal, making it suitable for human studies. Instead of
radiation coupling, we use inductive coupling to inject the pseudo-
FID (pFID). This requires an additional RF coil, called the injector
coil, placed close to the receive coil and fixed in position so that the
overlap of the flux lines for the two coils remains constant. Current
passing through the injector coil creates a magnetic field, B1ref,
that couples inductively with the main RF coil to create the
pseudo-peak. Since inductive coupling is the same mechanism by
which the magnetic field arising from excited nuclei in the sample
couples with the receive coil, all subsequent manipulations of the
data have an equal effect on the real and pseudo-signals.
We have previously conducted in vitro validation measurements
for spectroscopy [28] and imaging [29] applications. In this work
we apply the pFID method to quantify inorganic phosphate (Pi),
phosphocreatine (PCr) and adenosine triphosphate (ATP) concen-
trations using
31P spectroscopy measurements from resting human
tibialis anterior muscles. For these initial measurements in
humans, we implemented a protocol that imposed constraints on
the subject pool and the acquisition parameters. These constraints
were not dictated by the method we have developed but rather
were imposed to allow unambiguous validation against a more
established quantification method. Hence, while this work should
be considered developmental, it paves the way for more
sophisticated measurements in humans.
Our results reveal strong concordance between concentrations
obtained using the pFID method and those obtained using the
phantom replacement method [30–33], demonstrating feasibility
of our method for human applications. We also demonstrate that
the pFID method automatically compensates for differences in coil
loading conditions and so allows more expedient quantification of
metabolite content. We discuss how this method might be applied
to patients with mitochondrial disease and other disorders.
Methods
Prior approval for this study was obtained from the University
of Washington’s Human Subject Division. Written, informed
consent was obtained from each subject in accordance with
institutional protocol.
All experiments were conducted on a 4.7 T Bruker horizontal
bore magnet equipped with a Varian Inova spectrometer and
VNMR version 6.1. Before each measurement, the tune and
match capacitors were adjusted to yield 50 ohms impedance and
the Bo field was optimized by manually adjusting the shims. To
ensure consistent flip angles for all measurements, the transmitter
power was set to maximize the PCr signal with an RF pulse
duration of 110 msec. RF homogeneity concerns were addressed
by acquiring all measurements from samples that were much
larger than the sensitive volume of the surface coil and by using
spacers to ensure that the separation distance between the surface
coil and the measurement volume was the same for the phantom
measurements as it was for the in vivo measurements.
Probe design
Figure 1 contains a schematic of the hardware configuration
used for all measurements. A custom-built RF probe was used to
inject the pseudo-signal via inductive coupling. Details of the
probe design have been described previously [28]. In brief, the
probe consisted of a 20 mm diameter surface coil and a 1.5 mm
diameter, 2-turn injector coil, both formed from copper wire. The
main coil, which we will refer to as the surface coil, was tunable to
both
1H and
31P frequencies, 200.4 and 81.2 MHz respectively,
and was operated in both transmit and receive modes. The smaller
coil, which we call the injector coil, was used solely to inject the
pseudo-signal into the surface coil during data acquisition. The
geometry and orientation of the injector were designed to
minimize coupling between the injector coil and the sample.
The two coils were fixed in position relative to each other, with
approximately 1 mm separation distance between them, so that
the overlap between their flux lines was constant for all
measurements.
Data acquisition and processing
The data were acquired using a modified version of the Varian
SPULS pulse sequence and the equipment configuration (RF
synthesizer, RF amplifier, cabling, etc.) typically used for
spectroscopy. Acquisition parameters included repetition time
(TR)=15 sec, sweep width=10 kHz, block size =4096 points.
The long TR ensured that all metabolites were fully relaxed,
eliminating the need to measure and compensate for longitudinal
(T1) relaxation. SPULS is a nonlocalized pulse sequence with only
10 msec delay between the excitation pulse and data acquisition,
eliminating the need to measure and compensate for transverse
(T2) relaxation. The pulse sequence was modified to allow
transmission, via a second RF channel, of a pFID to the injector
coil during the data acquisition window. The pFID was a
monoexponential decay function with a time constant of 60 msec.
It was digitized with 4096 complex points, the same number used
for real data acquisition, and written to a text file that complied
with the Varian RF waveform format. To reduce the amplitude of
the B1 field created by the injector coil to approximately the same
amplitude as the field created by excited nuclei within the
acquisition volume, a 60 dB attenuator was inserted between the
second RF channel and the injector coil. To eliminate radiation
coupling between the injector coil circuit and the receive coil
circuit, semi-rigid cabling, with two layers of solid copper
shielding, was used to connect both the injector coil and surface
coil.
The following equation was used to determine metabolite
content [3]:
Cm~1:41Cref
Am
Ap
Ap,ref
Am,ref
ð1Þ
where: Cm is the average in vivo metabolite concentration within
the measurement volume, Cref is the volumetrically-determined
concentration of the metabolite analog used during the calibration
session (see below), Am and Ap are the amplitudes of the metabolite
and pseudo-signal peaks, respectively, acquired during the in vivo
session, and Am,ref and Ap,ref are the amplitudes of the metabolite
analog and pseudo-signal peaks, respectively, acquired during the
calibration session. The scale factor, 1.41, was used to convert the
units from mmol/L of muscle tissue to mmol/L of cellular water
[34]. The amplitudes of the spectral peaks were determined using
the Advanced Method for Accurate, Robust and Efficient Spectral
(AMARES) time domain fitting algorithm [35] as included in the
Synthetic MR Signal Injection
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package [36].
In vivo data were acquired from 5 normal male subjects whose
subcutaneous lipid layer thickness above the tibialis anterior
compartment was between 3.5 and 4.7 mm, as confirmed from a
scout image acquired with the surface coil. The constraint on lipid
layer thickness ensured that the distance between the surface coil
and the muscle tissue was consistent for all subjects. The
calibration measurements were also acquired with approximately
the same distance (4 mm, see below) between the measurement
volume and the surface coil. These steps ensured that all signals
were acquired from the same sensitive volume of the surface coil,
which varies as a function of distance from the plane defined by
the surface coil [37,38]. Average in vivo metabolite concentrations
were quantified for Pi, PCr, and ATP. The ATP concentration
was determined from the average of the aATP and cATP
moieties.
Calibration measurements
Calibration sessions were required to determine the reference
amplitudes, Am,ref and Ap,ref, in equation 1. The calibration data
were acquired from a phantom containing a volumetrically-
determined 75 mM sodium phosphate (NaH2PO4) concentration
using the same pulse sequence and acquisition parameters used for
the in vivo data. Agarose spacers with 4 mm thickness,
approximately the same thickness as the subcutaneous lipid layer
in all subjects, were placed between the phantom and the surface
coil to ensure that the calibration measurements were acquired
from the same sensitive volume of the surface coil as the in vivo
measurements.
Phantom replacement method
The phantom replacement method [30–33] was implemented
using equation 1 after eliminating the two terms corresponding to
the pseudo-signal, Ap and Ap,ref. This quantification method
assumes that RF coil loading conditions are the same for the
calibration phantom measurements as they are for the in vivo
measurements. This constraint was met by adjusting the salt
(NaCl) concentration in the agarose spacer until the Q value of the
surface coil was approximately the same as for the in vivo
measurements. The empirically determined salt concentration that
satisfied this constraint was 75 mM and the calibration data
obtained during this session are referred to as the ‘‘properly
loaded’’ calibration data.
To demonstrate immunity of the pFID measurements to
differences in coil loading conditions, calibration data were also
acquired using two additional agarose spacers. These spacers were
also 4 mm thick but one contained no salt, and loaded the surface
coil less than the in vivo measurements, and one contained
200 mM salt and loaded the surface coil more than the in vivo
measurements. The calibration data obtained with no salt in the
spacer are referred to as ‘‘underloaded’’. The calibration data
obtained with 200 mM salt in the spacer are referred to as
‘‘overloaded’’. Hence, each metabolite concentration was calcu-
lated in six different ways; three calculations using the pFID
method with calibration data obtained with an underloaded,
properly loaded, and overloaded surface coil, and three corre-
sponding concentrations using the phantom replacement method.
The metabolite concentrations obtained using the phantom
replacement method and the properly loaded calibration data
are referred to as the nominal concentrations and were considered
the gold standard against which all other results were compared.
Results
Figure 2 shows an example of an in vivo spectrum acquired
from the tibialis anterior compartment of one subject. The real
peaks corresponding to Pi, PCr and the c, a, and b ATP moieties
appear with sufficient signal to noise ratio (SNR) to allow
reasonable estimates of their tissue content.
Figure 3 shows the average Pi, PCr, and ATP concentrations
within the measurement volume from all 5 subjects. The x-axes in
the graphs are the nominal concentrations as determined using the
phantom replacement method and the calibration measurements
that were acquired with the surface coil loaded the same as it was
for the in vivo measurements. The dashed lines represent the lines
of identity. The concentrations determined using the pFID
method all fall close to the line of identity, demonstrating that
the calculations are independent of the coil loading conditions.
The pFID values also fall well within the range of values reported
in the literature [34]. In contrast, the concentrations determined
using the phantom replacement method are highly dependent on
coil loading conditions. When the surface coil was overloaded
during the calibration session, the phantom replacement method
consistently overestimated the metabolite concentrations by about
10%. When the surface coil was underloaded during the
calibration session, the phantom replacement method consistently
underestimated the concentrations by about 10%.
The same pattern is clear in the bar charts of Figure 4. When
the pFID method was used, the calculated concentrations for
individual subjects and the mean concentrations for all subjects
were independent of coil loading conditions and agreed with the
nominal concentrations. When the phantom replacement method
was used, the calculated concentrations were strongly dependent
on coil loading conditions.
Figure 1. The key hardware components required to inject the pseudo-signal. Prior to execution of the pulse sequence, a Unix macro was
used to create a digitized waveform describing the desired pseudo-signal. The pulse sequence read the waveform and sent it to the second RF
channel (RF2). The pseudo-signal passed through an external attenuator (Ext atten) before being fed to the injector coil. During sequence execution,
the surface coil was operated in transmit/receive mode while the injector coil was used only to transmit the pseudo-signal during the acquisition
window (AQ).
doi:10.1371/journal.pone.0015166.g001
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Aside from techniques that employ the principle of reciprocity
[39–41], the general algorithm most often used to convert MR
spectra to units of concentration is to establish the calibration
factor that describes the amplitude of the spectral peak generated
by excited reference molecules at a known concentration, and then
use that calibration factor to convert peaks of interest into units of
concentration [42–44]. The reference signal can come from an
internal substance in the tissue, such as water [45–49] or a
metabolite [50,51], whose concentration can be independently
determined and remains stable during the course of the
measurement. Internal reference signals can be acquired with
the sample of interest properly positioned in the RF coil, which
automatically compensates for coil loading. Unfortunately, there is
no reliable reference signal that allows this method to be broadly
applied to in vivo
31P measurements [41].
The reference signal can also come from an external substance
present at a known concentration in a phantom. The external
signal can be acquired from a vial placed outside the subject but
within the sensitive volume of the RF coil [52–57]. This
compensates for coil loading but is prone to problems with B1
sensitivity since the reference signal is necessarily acquired from a
different location in the RF coil than the sample of interest. Also,
the reference substance must resonate at a frequency that is
distinct from the peaks of interest and this can be problematic in
crowded spectra.
Problems with B1 sensitivity and overlap between peaks can be
addressed by acquiring the external reference signal in a separate
calibration session [30,58–60]. This method is often referred to as
the phantom replacement method or the replace and match
method. A critical constraint for proper implementation is that the
calibration phantom and the sample of interest must generate the
same load on the RF coil. This is a difficult constraint to meet for
human measurements because it requires accurate estimation of
the in vivo loading conditions, which can vary widely, and the
tedious fabrication of multiple phantoms that replicate them.
The results in Figures 3 and 4 demonstrate that the pFID
method provides a robust calibration factor that is immune to coil
loading conditions and allows accurate noninvasive assessment of
metabolite concentrations in humans. The Pi, PCr, and ATP
concentrations determined with the pFID method were consistent,
in concordance with the nominal concentrations, and fell well
within the range of normal values reported in the literature. In
contrast, the concentrations determined with the phantom
replacement method were clearly erroneous when in vivo coil
loading conditions were not properly replicated during the
calibration session. Immunity to coil loading conditions is perhaps
the most important advantage of the pFID approach because it
removes a substantial burden and potential source of error that is
inherent with other MR quantification methods.
For this developmental study, our subject pool was limited to
those with a specific lipid layer thickness and therefore the same
offset distance between the RF coil and the muscle tissue. This
constraint was imposed because we used a surface coil, and
Figure 2. A sample in vivo spectrum with real peaks and the
artificially injected pseudo-peak. The Pi, PCr and the c, a, and b
moieties of ATP appear at about 2.5, 0.5, 22.5, 25.0, 210, and
218.5 ppm, respectively. The pseudo-peak appears at 41 ppm. The
amplitude, frequency, phase, and line-width of the pseudo-peak are
determined by the digitized waveform transmitted by the RF
synthesizer and are easily adjusted.
doi:10.1371/journal.pone.0015166.g002
Figure 3. Concentrations determined by the pFID method are accurate and independent of coil loading conditions. The nominal
concentrations (x-axes) were determined using the phantom replacement method and calibration measurements obtained from a phantom that
replicated in vivo coil loading conditions. The nominal concentrations reflect the normal ranges of Pi, PCr and ATP expected in healthy male subjects.
All three sets of pFID measurements fall very close to the lines of identity (dashed lines), validating that this method allows accurate quantification of
metabolite content for a wide range of coil loading conditions. In contrast, the concentrations determined using the phantom replacement method
were invalid when in vivo coil loading conditions were not replicated in the calibration session. When the calibration phantom overloaded the coil,
the phantom replacement method overestimated the in vivo concentrations. When the phantom underloaded the coil, the phantom replacement
method underestimated the in vivo concentrations.
doi:10.1371/journal.pone.0015166.g003
Synthetic MR Signal Injection
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Our limited subject pool ensured that all the in vivo metabolite
signals were acquired from the same sensitive volume of the RF
coil as the calibration data acquired from the reference phantom.
This constraint could be removed by using an acquisition coil with
a sufficiently large homogenous region to allow volume localiza-
tion or by conducting additional calibration measurements with a
range of offsets from the acquisition coil. To allow straightforward
validation, our data were acquired using a simple pulse-acquire
sequence with a long repetition time, precluding the need to
correct for relaxation/saturation effects. More efficient data
acquisition and more complicated pulse sequences could be
accommodated if additional relaxation measurements were
acquired to allow correction for T1 and T2 effects.
Our results demonstrate that the pFID method allows expedient
and accurate determination of in vivo metabolite content. The
protocol we describe could be readily adapted for use in pediatric
patients with suspected mitochondrial disorder, where marked
alterations in phosphorous metabolites have been observed
[61–63]. Robust
31P-MRS measurements in muscle could be
used to monitor therapy in these patients [64], after establishing
the normal pattern of variation during development [65,66]. The
pFID method is also applicable for other MR-visible nuclei. We
are currently building a pFID probe for use in human brain
measurements, where quantitative MRS could enhance the ability
to distinguish tumor types [67,68] and assess neurotoxicity
following radiation treatment [69]. We also plan to build a
19F
probe, which could be used to determine whole brain fluorine
content in subjects being treated with fluorinated antidepressant or
antipsychotic medications.
The main disadvantage to using inductive coupling for injecting
the pseudo-signal is that it currently requires a specially modified
RF probe that includes an injector coil. While the cost of the
modification is relatively low, this might restrict its use to research
sites that have the required expertise. To address this, we are
currently exploring the feasibility of using a detachable injector
coil that would be compatible with multiple RF coils and would
reduce the burden of implementation.
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